BDKRB1 and inflammatory bowel disease: The upregulation of kinin B1R in inflammation models relies in part on TNF‐α, a well‐established target for IBD drug therapy.[28] The therapeutic effect of anti‐TNF‐α agents such as infliximab in IBD may be due in part to the inhibition of kinin B1R expression, and selective kinin B1R antagonists have demonstrated potent anti‐inflammatory effects in IBD models.[29] We analyzed scRNA‐seq data from the CCD‐18Co colon fibroblast cell line treated with various inflammatory factors,[30] BDKRB1 expression was highest in IL‐1β and TNF‐α groups (Figure S4A–D, Supporting Information).